Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively

Drug Metabolism and Disposition

Volumn 30, Issue 6, 2002, Pages 631-635

  Wen, Xia ^a   Wang, Jun sheng ^a   Backman, Janne T ^a   Laitila, Jouko ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2AC; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; PACLITAXEL; SULFAMETHOXAZOLE; TOLBUTAMIDE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROXYLATION; IC 50; LIVER MICROSOME; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MALE; MICROSOMES, LIVER; RECOMBINANT PROTEINS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFAMETHOXAZOLE; TRIMETHOPRIM;

EID: 0036266778     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.6.631     Document Type: Article

References (25)

1. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quirolines
2. Distribution of trimethoprim-sulfamethoxazole in tissues of rhesus monkeys
3. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes
4. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry
5. Sulfamethoxazole and trimethoprim combination
6. Lack of effect of co-trimoxazole on the pharmacokinetics and pharmacodynamics of nifedipine
7. Trimethoprim: Mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications
8. The effect of different sulfonamides on phenytoin metabolism in man
9. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
10. Symptomatic hypoglycemia secondary to a glipizidetrimethoprim/sulfamethoxazole drug interaction
11. Lack of influence of co-trimoxazole on theophylline pharmacokinetics
12. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments
13. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: Roles of cytochromes P450 2C9, 2C19, and 3A4
14. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP2C9
15. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole
16. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: An approach to predict the contribution with relative activity factor
17. The xenobiotic inhibitor profile of cytochrome P4502C8
18. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man
19. Comparison of pharmacokinetics of the combination trimethoprim and sulfamethoxazole in patients with liver diseases and healthy persons
20. Simple inhibition system
21. High-performance liquid chromatography with electrochemical detection of chlorzoxazone and its hydroxy metabolite in serum using solid-phase extraction
22. In vitro approaches to predicting drug interactions in vivo
23. Human cytochrome P-450 3A4 in vitro drug-drug interaction patterns are substrate-dependent
24. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: Preferential inhibition of cytochrome P4502C9 (CYP2C9)
25. Cotrimoxazole as an inhibitor of oxidative drug metabolism: Effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition